HRP20221067T1 - Postupak priprave 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona i njegovih soli - Google Patents
Postupak priprave 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona i njegovih soli Download PDFInfo
- Publication number
- HRP20221067T1 HRP20221067T1 HRP20221067TT HRP20221067T HRP20221067T1 HR P20221067 T1 HRP20221067 T1 HR P20221067T1 HR P20221067T T HRP20221067T T HR P20221067TT HR P20221067 T HRP20221067 T HR P20221067T HR P20221067 T1 HRP20221067 T1 HR P20221067T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- group
- solvent
- reaction mixture
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 7
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 31
- 239000011541 reaction mixture Substances 0.000 claims 23
- 239000002904 solvent Substances 0.000 claims 22
- 238000006243 chemical reaction Methods 0.000 claims 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 7
- 239000002585 base Substances 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 7
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims 6
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 6
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims 5
- 239000002841 Lewis acid Substances 0.000 claims 5
- 150000007517 lewis acids Chemical class 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 5
- 239000002244 precipitate Substances 0.000 claims 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 229910021645 metal ion Inorganic materials 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 150000007524 organic acids Chemical class 0.000 claims 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical group [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 239000003880 polar aprotic solvent Substances 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 2
- -1 tert-butyldimethylsilyl (TBDMS) Chemical class 0.000 claims 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 claims 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims 1
- 150000008041 alkali metal carbonates Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000005104 aryl silyl group Chemical group 0.000 claims 1
- 239000012298 atmosphere Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 claims 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 claims 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 claims 1
- JGUQDUKBUKFFRO-CIIODKQPSA-N dimethylglyoxime Chemical compound O/N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-CIIODKQPSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 239000012299 nitrogen atmosphere Substances 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 claims 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000005270 trialkylamine group Chemical group 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/127—Preparation from compounds containing pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (32)
1. Postupak, naznačen time što se sastoji u:
reakciji spoja Formule II:
[image]
,
gdje je PG zaštitna skupina, a LG1 je izlazna skupina,
s etilen-oksidom u prisutnosti
(a) alkillitija i bakrene(I) soli; ili
(b) alkillitija i Lewisove kiseline, te
otapala,
kako bi se dobilo spoj Formule III:
[image]
.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je PG zaštitna skupina koju se bira iz skupine koju čine sililna zaštitna skupina, tetrahidropiranil, metoksimetil, te benzil; gdje se po mogućnosti etilen-oksid, alkillitij, te bakrenu(I) sol ili Lewisovu kiselinu dodaje u reakcijsku smjesu koja sadrži spoj Formule II uz održavanje temperature reakcijske smjese ispod –20 °C; gdje se poželjnije etilen-oksid, alkillitij, te bakrenu(I) sol ili Lewisovu kiselina dodaje uz održavanje temperature reakcijske smjese ispod –55 °C; i gdje se poželjnije etilen-oksid dodaje u reakcijsku smjesu nakon prvog dodavanja alkillitija.
3. Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se reakcijsku smjesu pusti da se zagrije do sobne temperature nakon dodavanja reagensa.
4. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što se reakciju provodi u prisutnosti alkillitija i bakrenog(I) jodida; gdje se po mogućnosti alkillitij i bakreni(I) jodid dodaje uz održavanje temperature reakcije ispod –55 °C.
5. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u:
reakciji spoja Formule II:
[image]
,
gdje je PG zaštitna skupina koju se bira iz skupine koju čine sililna zaštitna skupina, tetrahidropiranil, te metoksimetil, a LG1 je izlazna skupina,
s etilen-oksidom u prisutnosti alkillitija i bakrenog(I) jodida, te
otapala, gdje
temperaturu reakcije se održava ispod –20 °C prilikom dodavanja alkillitija i bakrenog(I) jodida u reakcijsku smjesu,
kako bi se dobilo spoj Formule III:
[image]
.
6. Postupak u skladu s patentnim zahtjevom 5, naznačen time što se etilen-oksid dodaje u reakcijsku smjesu nakon prvog dodavanja alkillitija; gdje se po mogućnosti alkillitij i bakreni(I) jodid dodaje uz održavanje temperature reakcije ispod –55 °C; i gdje se poželjnije reakcijsku smjesu pusti da se zagrije do sobne temperature nakon dodavanja reagensa.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što se otapalo bira iz skupine koju čine nepolarno neprotonsko organsko otapalo i polarno neprotonsko organsko otapalo, ili njihova smjesa; gdje je po mogućnosti otapalo nepolarno neprotonsko organsko otapalo; i gdje je poželjnije otapalo dietil-eter ili tert-butil-metil-eter, ili njihova smjesa.
8. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se postupak sastoji u:
(a) reakciji spoja koji ima Formulu II:
[image]
,
s alkillitijem u prvom otapalu na temperaturi kako bi se dobilo prvu reakcijsku smjesu;
gdje:
temperatura je ispod –20 °C;
PG je zaštitna skupina koju se bira iz skupine koju čine sililna zaštitna skupina, tetrahidropiranil, metoksimetil, te benzil; i
LG1 je izlazna skupina, te bilo
(b) dodavanju otopine etilen-oksida u drugom otapalu na navedenoj temperaturi u navedenu prvu reakcijsku smjesu na navedenoj temperaturi kako bi se dobilo drugu reakcijsku smjesu; i
(c) dodavanju bakrene(I) soli ili Lewisove kiseline u navedenu drugu reakcijsku smjesu na navedenoj temperaturi kako bi se dobilo treću reakcijsku smjesu koja sadrži spoj koji ima Formulu III; ili
(b) dodavanju bakrene(I) soli ili Lewisove kiseline u navedenu prvu reakcijsku smjesu na navedenoj temperaturi kako bi se dobilo drugu reakcijsku smjesu; i
(c) dodavanju otopine etilen-oksida u drugom otapalu na navedenoj temperaturi u navedenu drugu reakcijsku smjesu na navedenoj temperaturi kako bi se dobilo treću reakcijsku smjesu koja sadrži spoj koji ima Formulu III.
9. Postupak u skladu s patentnim zahtjevom 8, naznačen time što je temperatura ispod –55 °C.
10. Postupak u skladu s patentnim zahtjevom 8 ili 9, naznačen time što se navedenu treću reakcijsku smjesu pusti da se zagrije do temperature od 20 °C-25 °C; gdje se po mogućnosti navedenu treću reakcijsku smjesu drži na 20 °C-25 °C u trajanju od najmanje 4 sata, u trajanju od najmanje 6 sati, u trajanju od najmanje 8 sati, ili u trajanju od najmanje 10 sati.
11. Postupak u skladu s bilo kojim od patentnih zahtjeva 8-10, naznačen time što se svakog od navedenog prvog otapala i navedenog drugog otapala neovisno bira iz skupine koju čine nepolarno neprotonsko organsko otapalo i polarno neprotonsko organsko otapalo, ili njihova smjesa; i gdje se po mogućnosti navedeno prvo otapalo i navedeno drugo otapalo bira iz skupine koju čine dietil-eter i metil-tert-butil-eter, ili njihova smjesa.
12. Postupak u skladu s bilo kojim od patentnih zahtjeva 8-11, naznačen time što postupak uključuje bakreni(I) jodid.
13. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što se PG bira između sililnih zaštitnih skupina; gdje je po mogućnosti PG alkil- ili arilsililna skupina, ili njihova kombinacija; gdje je poželjnije PG trialkilsililna skupina; gdje je poželjnije PG TBDMS, TMS, TES, TIPS ili TBDPS; i gdje je poželjnije PG tert-butildimetilsilil (TBDMS).
14. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je LG1 klorid, bromid, jodid ili fluorid; gdje je po mogućnosti LG1 bromid; gdje je alkillitij C1-6 alkillitij; i gdje je po mogućnosti alkillitij n-butillitij.
15. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-14, naznačen time što dodatno uključuje izoliranje navedenog spoja Formule III i izborno pročišćavanje izoliranog spoja Formule III.
16. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-15, naznačen time što dodatno uključuje reakciju navedenog spoja Formule III s R1-Cl, gdje je R1 organosulfonat, u prisutnosti prve baze kako bi se dobilo spoj Formule IV:
[image]
;
gdje je po mogućnosti organosulfonat tosilna skupina (Ts) ili mesilna skupina (Ms); gdje je poželjnije organosulfonat tosilna skupina; gdje je poželjnije prva baza jedno ili više od amina, kvaternarne amonijeve soli u kombinaciji s vodenom otopinom hidroksida alkalnog metala, tetrabutilamonijevhidroksid, ili hidroksid alkalnog metala; gdje je poželjnije prva baza kvaternarna amonijeva sol u kombinaciji s vodenom otopinom hidroksida alkalnog metala; i gdje je poželjnije prva baza tetra-n-butilamonijev bromid u vodenoj otopini NaOH.
17. Postupak u skladu s patentnim zahtjevom 16, naznačen time što se reakciju provodi u prisutnosti otapala.
18. Postupak u skladu s patentnim zahtjevom 16 ili 17, naznačen time što dodatno uključuje reakciju navedenog spoja Formule IV s 4-hidroksibenzaldehidom:
[image]
u prisutnosti druge baze i otapala kako bi se dobilo spoj Formule V:
[image]
;
gdje
po mogućnosti je druga baza karbonat alkalnog metala, trialkilamin ili alkoksid alkalnog metala; gdje je poželjnije druga baza K2CO3; gdje se poželjnije otapalo bira iz skupine koju čine toluen, etanol, 2-propanol, THF, 2-MeTHF, te voda, ili njihova smjesa; i gdje je poželjnije otapalo smjesa toluena i etanola.
19. Postupak u skladu s patentnim zahtjevom 18, naznačen time što dodatno uključuje dodavanje vode u reakcijsku smjesu; gdje se po mogućnosti količina dodatne vode kreće od 2% do 7% vol/vol; gdje po mogućnosti dodatno uključuje izoliranje i pročišćavanje navedenog spoja Formule V; i gdje se po mogućnosti navedeno pročišćavanje sastoji u ekstrahiranju vodenom otopinom bisulfita.
20. Postupak u skladu s patentnim zahtjevom 18 ili 19, naznačen time što dodatno uključuje reakciju navedenog spoja Formule V s 2,4-tiazolidindionom:
[image]
u prisutnosti piperidina i izborno otapala, te izborno organske kiseline, kako bi se dobilo spoj Formule VI:
[image]
.
21. Postupak u skladu s patentnim zahtjevom 20, naznačen time što se reakciju provodi u prisutnosti otapala; gdje se po mogućnosti otapalo bira iz skupine koju čine toluen, niži alkohol, heksan, te cikloheksan, ili njihova smjesa; i gdje je poželjnije otapalo toluen ili metanol, ili njihova smjesa.
22. Postupak u skladu s patentnim zahtjevom 20 ili 21, naznačen time što se reakciju provodi u prisutnosti organske kiseline; gdje je po mogućnosti organska kiselina octena kiselina ili mravlja kiselina.
23. Postupak u skladu s bilo kojim od patentnih zahtjeva 20-22, naznačen time što se reakciju provodi na temperaturi od 45 °C do 80 °C; gdje je po mogućnosti otapalo metanol, a postupak se provodi na 47 °C.
24. Postupak u skladu s bilo kojim od patentnih zahtjeva 20-23, naznačen time što dodatno uključuje reduciranje navedenog spoja Formule VI kako bi se dobilo spoj Formule VII:
[image]
;
gdje po mogućnosti
redukciju se provodi puštanjem da navedeni spoj Formule VI reagira s reducensom u prisutnosti metalnog iona i kompleksirajućeg sredstva za metalni ion; gdje je poželjnije reducens NaBH4, metalni ion je Co2+, a ligand je dimetilglioksim; gdje se poželjnije pH reakcijske smjese održava na pH 9,5 do 10,5; gdje se poželjnije redukciju provodi u inertnoj atmosferi; i gdje se poželjnije redukciju provodi u atmosferi dušika.
25. Postupak u skladu s patentnim zahtjevom 24, naznačen time što dodatno uključuje uklanjanje zaštitne s navedenog spoja Formule VII, te izbornu dodatnu obradu kiselinom, kako bi se dobilo spoj Formule I:
[image]
,
ili njegovu farmaceutski prihvatljivu sol; gdje se po mogućnosti uklanjanje zaštite s navedenog spoja Formule VII i nastajanje soli provodi istodobno; gdje poželjnije dodatno uključuje taloženje navedenog spoja Formule I, ili njegove farmaceutski prihvatljive soli; gdje se poželjnije navedeno taloženje provodi obradom reakcijske smjese polarnim neprotonskim otapalom na povišenoj temperaturi, gdje se zatim reakcijsku smjesu pusti da se ohladi do sobne temperature; i gdje je poželjnije polarno neprotonsko otapalo acetonitril.
26. Postupak u skladu s patentnim zahtjevom 25, naznačen time što dodatno uključuje izoliranje navedenog taloga koji sadrži spoj Formule I, ili njegovu farmaceutski prihvatljivu sol; gdje se po mogućnosti navedeni talog izolira filtriranjem kako bi se dobilo izolirani talog; gdje se poželjnije navedeni izolirani talog ispire acetonitrilom i/ili smjesom acetonitrila i vode; i gdje poželjnije postupak uključuje dodatno pročišćavanje navedenog izoliranog taloga.
27. Postupak u skladu s patentnim zahtjevom 25 ili 26, naznačen time što se navedeni spoj Formule I izolira u obliku svoje farmaceutski prihvatljive soli.
28. Postupak u skladu s patentnim zahtjevom 25 ili 26, naznačen time što je navedeni spoj Formule I hidrokloridna sol 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona.
29. Postupak u skladu s bilo kojim od patentnih zahtjeva 25-28, naznačen time što dodatno uključuje deuteriranje spoja Formule I, ili njegove farmaceutski prihvatljive soli.
30. Postupak u skladu s patentnim zahtjevom 1 ili 8, naznačen time što se navedeni spoj Formule II pripravlja zaštitom hidroksilne skupine u spoju Formule VIII:
[image]
,
gdje je LG1 izlazna skupina, zaštitnom skupinom PG, gdje se PG bira iz skupine koju čine sililna zaštitna skupina, tetrahidropiranil, metoksimetil, te benzil, kako bi se dobilo spoj Formule II; gdje po mogućnosti navedeni spoj Formule VIII reagira sa silil-kloridom, kojeg se bira iz skupine koju čine TBDMS-Cl, TMS-Cl, TBDPS-Cl, te TIPS-Cl, i imidazolom u visokoj koncentraciji u DMF-u.
31. Postupak u skladu s patentnim zahtjevom 30, naznačen time što se navedeni spoj Formule VIII pripravlja reakcijom spoja Formule IX:
[image]
,
gdje je LG1 izlazna skupina, s CH3CHO u prisutnosti alkilmagnezijevog halogenida i otapala kako bi se dobilo spoj Formule VIII.
32. Spoj Formule III:
[image]
,
gdje je PG zaštitna skupina koju se bira iz skupine koju čine sililna zaštitna skupina, te benzil, naznačen time što ga se pripravlja postupkom u skladu s bilo kojim od patentnih zahtjeva 1-15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382648 | 2016-12-23 | ||
PCT/IB2017/058374 WO2018116281A1 (en) | 2016-12-23 | 2017-12-22 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
EP17829042.5A EP3559010B1 (en) | 2016-12-23 | 2017-12-22 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221067T1 true HRP20221067T1 (hr) | 2022-11-25 |
Family
ID=57799523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221067TT HRP20221067T1 (hr) | 2016-12-23 | 2017-12-22 | Postupak priprave 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona i njegovih soli |
Country Status (18)
Country | Link |
---|---|
US (2) | US11124505B2 (hr) |
EP (1) | EP3559010B1 (hr) |
JP (2) | JP7294661B2 (hr) |
KR (1) | KR102609373B1 (hr) |
CN (1) | CN110198945B (hr) |
BR (1) | BR112019012972B1 (hr) |
CA (1) | CA3046744A1 (hr) |
DK (1) | DK3559010T3 (hr) |
ES (1) | ES2926580T3 (hr) |
HR (1) | HRP20221067T1 (hr) |
HU (1) | HUE059604T2 (hr) |
IL (1) | IL267557B (hr) |
LT (1) | LT3559010T (hr) |
MX (1) | MX2019007327A (hr) |
PL (1) | PL3559010T3 (hr) |
PT (1) | PT3559010T (hr) |
SI (1) | SI3559010T1 (hr) |
WO (1) | WO2018116281A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11124505B2 (en) | 2016-12-23 | 2021-09-21 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
MX2020013182A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales. |
KR20210031435A (ko) | 2018-06-06 | 2021-03-19 | 미노릭스 테라퓨틱스 에스.엘. | 치료학적 유효량의 5-[[4-[2-[5-(1-히드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온을 투여하는 방법 |
US11957670B2 (en) | 2018-06-06 | 2024-04-16 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
WO2024141951A1 (en) | 2022-12-28 | 2024-07-04 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018501A1 (en) * | 1991-04-11 | 1992-10-29 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
US6067749A (en) | 1996-07-11 | 2000-05-30 | Tasmanian Alkaloids Pty. Ltd. | Papaver somniferum strain with high concentration of thebaine and oripavine |
US5869669A (en) | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
HUP0304096A2 (hu) | 2003-12-19 | 2005-08-29 | Richter Gedeon Vegyészeti Gyár Rt. | Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei |
GB0421687D0 (en) | 2004-09-30 | 2004-11-03 | Johnson Matthey Plc | Preparation of opiate analgesics |
WO2006087178A1 (en) | 2005-02-16 | 2006-08-24 | Micromet Ag | Use of activated polymers for separation of protein and polypeptide multimers |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素5員複素環化合物 |
KR20150003766A (ko) * | 2012-04-26 | 2015-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체 |
EP2968298B1 (en) | 2013-03-14 | 2018-01-31 | Deuterx, LLC | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
MX2016012687A (es) | 2014-04-02 | 2017-04-27 | Minoryx Therapeutics S L | Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central. |
US11124505B2 (en) | 2016-12-23 | 2021-09-21 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
-
2017
- 2017-12-22 US US16/470,866 patent/US11124505B2/en active Active
- 2017-12-22 BR BR112019012972-3A patent/BR112019012972B1/pt active IP Right Grant
- 2017-12-22 SI SI201731203T patent/SI3559010T1/sl unknown
- 2017-12-22 WO PCT/IB2017/058374 patent/WO2018116281A1/en unknown
- 2017-12-22 PL PL17829042.5T patent/PL3559010T3/pl unknown
- 2017-12-22 CN CN201780084302.3A patent/CN110198945B/zh active Active
- 2017-12-22 EP EP17829042.5A patent/EP3559010B1/en active Active
- 2017-12-22 HR HRP20221067TT patent/HRP20221067T1/hr unknown
- 2017-12-22 DK DK17829042.5T patent/DK3559010T3/da active
- 2017-12-22 LT LTEPPCT/IB2017/058374T patent/LT3559010T/lt unknown
- 2017-12-22 HU HUE17829042A patent/HUE059604T2/hu unknown
- 2017-12-22 KR KR1020197021529A patent/KR102609373B1/ko active IP Right Grant
- 2017-12-22 CA CA3046744A patent/CA3046744A1/en active Pending
- 2017-12-22 MX MX2019007327A patent/MX2019007327A/es unknown
- 2017-12-22 ES ES17829042T patent/ES2926580T3/es active Active
- 2017-12-22 JP JP2019534154A patent/JP7294661B2/ja active Active
- 2017-12-22 PT PT178290425T patent/PT3559010T/pt unknown
-
2019
- 2019-06-20 IL IL267557A patent/IL267557B/en unknown
-
2021
- 2021-09-20 US US17/479,838 patent/US11731963B2/en active Active
-
2023
- 2023-02-06 JP JP2023016009A patent/JP2023052918A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20190100300A (ko) | 2019-08-28 |
EP3559010A1 (en) | 2019-10-30 |
US11124505B2 (en) | 2021-09-21 |
JP2020502228A (ja) | 2020-01-23 |
IL267557A (en) | 2019-08-29 |
MX2019007327A (es) | 2019-09-02 |
LT3559010T (lt) | 2022-10-10 |
IL267557B (en) | 2021-10-31 |
EP3559010B1 (en) | 2022-06-08 |
CN110198945A (zh) | 2019-09-03 |
CA3046744A1 (en) | 2018-06-28 |
CN110198945B (zh) | 2023-06-27 |
WO2018116281A1 (en) | 2018-06-28 |
BR112019012972A2 (pt) | 2019-12-31 |
JP2023052918A (ja) | 2023-04-12 |
KR102609373B1 (ko) | 2023-12-01 |
US20190389852A1 (en) | 2019-12-26 |
SI3559010T1 (sl) | 2022-10-28 |
JP7294661B2 (ja) | 2023-06-20 |
ES2926580T3 (es) | 2022-10-27 |
US20220204496A1 (en) | 2022-06-30 |
HUE059604T2 (hu) | 2022-11-28 |
US11731963B2 (en) | 2023-08-22 |
PL3559010T3 (pl) | 2022-11-21 |
BR112019012972B1 (pt) | 2023-04-18 |
DK3559010T3 (da) | 2022-08-15 |
PT3559010T (pt) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221067T1 (hr) | Postupak priprave 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiona i njegovih soli | |
JP2012082227A5 (hr) | ||
EP1809625A1 (en) | Methods for preparing indazole compounds | |
JP2020502228A5 (hr) | ||
US20170233400A1 (en) | Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates | |
JP2008511764A5 (hr) | ||
JP2010510976A5 (hr) | ||
UA101482C2 (ru) | Способ получения 2'-дезокси-5-азацитидина (децитабина) | |
CN103351401A (zh) | 一种含硫硅烷偶联剂及其制备方法 | |
JP4128633B2 (ja) | 2−置換−1−(テトラゾール−5−イル)ベンゼン合成のためのオルトメタル化方法 | |
US9938297B2 (en) | Process for the synthesis of everolimus and intermediates thereof | |
JP2005516064A5 (hr) | ||
WO2011127143A1 (en) | Process for preparing benzoxaboroles | |
CN109529928B (zh) | 一种催化剂体系及利用其制备嘧菌酯或其中间体的方法 | |
US20110034690A1 (en) | Process for the preparation of pure prulifloxacin | |
JP2016519669A5 (hr) | ||
JPS6029707B2 (ja) | 新規イミダゾ−ル化合物,該化合物の合成法および該化合物を用いる銀金属の防錆方法 | |
RU2007146394A (ru) | Способы получения гетероциклических соединений | |
WO2006011157A3 (en) | Methods for the preparation of aryl piperazinyl-heterocyclic compounds | |
EP0977740A1 (en) | Methods for synthesizing 2-substituted imidazoles | |
CN105452245A (zh) | [1,2,4]-三唑并[4,3-a]吡啶的制备方法 | |
CN1117746C (zh) | 制备取代的吡啶类化合物的方法及由该方法获得的吡啶类化合物 | |
JP2013067601A (ja) | テトラシアノボレート塩の製造方法 | |
JP3149279B2 (ja) | シクロプロペノン誘導体 | |
US20060058521A1 (en) | Processes for preparation of organic compounds |